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Sir,
In response to the lack of detection of HPV in MDA-MB-175VII
and SK-Br-3 cell lines, we note that the authors have
not followed the methods as set out (Heng et al, 2009). Critically,
Peran et al (2010) relied on single rounds of standard and reverse
transcription (RT)–PCR. In our report, we specifically indicate the
use of nested PCR (using the MY11/MY9 followed by GP5/GP6
combination for amplification of the L1 region of HPV). The use of
nested primers was necessary to increase the sensitivity without
compromising the specificity of the standard PCR.
The requirement for the increased sensitivity for detection of
HPV in the breast cancer cell lines may indicate less than one copy
of HPV per cell, unlike the situation in cervical cancer cell lines
such as HeLa. Ever since reporting the detection of HPV-18 in the
MDA-MB-175VII and SK-Br-3 breast cancer cell lines, we have
endeavoured to further characterise the HPV genome present in
these cell lines. This analysis is by no means complete, but we
present our relevant preliminary findings here.
The breast cancer cell lines MDA-MB-175VII and SK-Br-3, and
all cell lines in our laboratory, have been subjected to ‘DNA
fingerprint’ analysis by SNP PCR (summarised in Table 1). All cell
lines have different DNA fingerprints, demonstrating that these
cell lines are not contaminated. In addition, we have confirmed
Table 1 DNA fingerprinting of HPV-containing breast cancer cell lines
Cell line/SNP marker
a D18S63 D18S452 D6S1035
Negative Negative Negative Negative
HeLa 1 (270) 1 (151) 2 (145, 151)
SiHa 2 (270, 284) 1 (151) 2 (143, 156)
C33A 2 (272, 290) 2 (161, 163) 2 (139, 151)
SK-Br-3 2 (282, 286) 1 (155) 2 (143, 151)
MDA-MB-175VII 2 (270, 286) 1 (155) 2 (150, 154)
175 Clone 1 2 (270, 286) 1 (155) 2 (150, 154)
175 Clone 2 2 (270, 286) 1 (155) 2 (150, 154)
175 Clone 3 2 (270, 286) 1 (155) 2 (150, 154)
175 Clone 4 2 (270, 286) 1 (155) 2 (150, 154)
175 Clone 5 2 (270, 286) 1 (155) 2 (150, 154)
175 Clone 6 2 (270, 286) 1 (155) 2 (150, 154)
aEight SNP markers from eight different loci were amplified by PCR using
chromogenically labelled primers. Only three of the SNP markers are shown. The
number of the bands from each allele (with the size of each band at that locus in
parentheses) from NSP PCR analysis gives a ‘DNA fingerprint’. Each cell line has a
unique DNA fingerprint, while the parental MDA-MB-175 cell line and each of the six
clones have identical DNA fingerprints, as expected.
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Figure 1 Mycoplasma testing of breast cancer cell lines. DNA isolated
from the cell line supernatant was amplified with the control and
mycoplasma-specific primers (Sigma LookOut Mycoplasma PCR Detection
Kit (MP0035)); products were resolved by electrophoresis in a 1.2%
agarose gel. The presence of the 259-bp band indicates the presence of
Mycoplasma sequences, while the 481-bp band indicates that the PCR
reaction worked. Lane 1: pUc-HinfI size marker, lane 2: Mycoplasma-
positive control, lane 3: negative control, lane 4: SK-Br-3.
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Figure 2 E6-reverse transcription–PCR. Lane 1: Puc/Hinf marker, lanes
2 and 3: cDNA from HeLa and MDA-MB-175VII, respectively, lane 4: HeLa
genomic DNA (postive control), lane 5: RT–PCR reaction without the RT
enzyme (RT control), lane 6: water (PCR-negative control). HeLa cDNA and
genomic DNA, and MDA-MB-175 VII cDNA, yield a positive band of 300bp,
indicating expression of E6 mRNA in both HeLa and MDA-MB-175VII cell
lines. Primer sequences: E6 forward primer, 50-CGGCGACCCTACAAGC
TAC-30,E 6r e v e r s ep r i m e r ,5 0-GCACCGCAGGCACCTTAT-30. Published online 20 April 2010
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shown in Figure 1).
We reported the amplification of the L1 region by PCR using
nested primers (MY/GP) from DNA isolated from both MDA-MB-
175VII and SK-Br-3 cell lines (Heng et al, 2009). This product was
also sequenced to confirm the identity of HPV-18. Here we report
that we have successfully amplified E6 by standard PCR from MDA-
MB-175VII DNA and by RT–PCR from RNA, indicating the presence
of E6 and the expression of E6 in these cells (Figure 2). The RT–PCR
bands from Figure 2 were isolated, purified and subjected to sequence
analysis. As shown in Figure 3, the sequence of this E6 region was
identical in HeLa and MDA-MB-17 5 V I Ic e l ll i n e s .T h i si sn o t
unexpected given that this region is functional and conserved.
Because of the difficulty in amplifying HPV in these breast cancer cells
and because these cell lines have been available and passaged in many
different laboratories over many years and may have changed
significantly over time, we subcloned (by limiting the dilution) the
MDA-MB-175VII cell line. Here we show that all six subclones of MDA-
MB-175VII have the same DNA fingerprint as the parental MDA-MB-
175VII cell line (Table 1), as expected. Interestingly, all the clones
contained a mixture of fusiform and epithelial-shaped cells, indicating
that the single clones vary or alternate in phenotype and that these two
forms (need to?) coexist for the continued proliferation of the cell line.
Only three of six MDA-MB-175VII clones isolated apparently
contained HPV as indicated by the successful amplification of the
L1 region by nested PCR and by in situ PCR as per Heng et al
(2009). Interestingly, the HPV-containing clones grew faster than
the clones without amplifiable HPV.
We have confirmed the presence of HPV in the nuclei of both
MDA-MB-175VII and SK-Br-3 cell lines by in situ PCR subsequent
to the report in Heng et al (2009).
By using a series of primers in the L1 region, it appears that the L1
sequence does not extend 50 far beyond GP5 in the MBA-MB-175VII
cell line. The region 30 of the L1 amplicon was extended at least as far
as 7244bp. This suggests that the HPV is fragmented and/or
incomplete and may indicate ‘hit-and-run’ oncogenesis as described
for HPV in Syrian hamster embryo cells (Iwasaka et al, 1992) and for
human mesothelial cells (De Silva et al, 1994). We are continuing our
analysis of the HPV sequence in MBA-MB-175VII and SK-Br-3 cell
lines, as well as in two other HPV-containing breast cancer cell lines
that are yet to be described and characterised.
We conclude that the HPV sequences are present as reported
(Heng et al, 2009). We suggest that the difficulty in detection is
possibly due to (i) the loss and/or fragmentation of the HPV
(suggesting hit-and-run transformation), and/or (ii) instability or
variability of the HPV-containing cell lines.
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CGGCGACCCT ACAAGCTACC TGATCTGTGC ACGGAACTGA ACACTTCACT GCAAGACATA GAAATAACCT
GTGTATATTG CAAGACAGTA TTGGAACTTA CAGAGGTATT TGAATTTGCA TTTAAAGATT TATTTGTGGT
GTATAGAGAC AGTATACCGC ATGCTGCATG CCATAAATGT ATAGATTTTT ATTCTAGAAT TAGAGAATTA
AGACATTATT CAGACTCTGT GTATGGAGAC ACATTGGAAA AACTAACTAA CACTGGGTTA TACAATTTAT
TAATAAGGTG CCTGCGGTGC CA
Figure 3 Sequencing of the E6 RT–PCR product in breast cancer cell line MDA-MB-175VII. The products from the RT–PCR were purified and
sequenced. The resultant sequence is shown and is identical to the E6 RT–PCR sequence obtained from the HeLa E6 RT–PCR analysis. The underlined
sequence is the forward E6 PCR primer.
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